Noteworthy

Nov 04, 2009
Pharmaceutical Executive
By Pharmaceutical Executive Editors
As the first generation of biologics patents expire, companies are jokeying for position in follow-on biologics.
Oct 19, 2009
By Pharmaceutical Executive Editors
Pharm Exec interviews some of this year's emerging leaders to learn their strategies for success.
Oct 02, 2009
Pharmaceutical Executive
By Pharmaceutical Executive Editors
How proper site activation and site enrollment can help you get the most from clinical trials.
Oct 01, 2009
Pharmaceutical Executive
Novartis CEO Daniel Vasella has built the Swiss firm into the fastest growing pharma in the world, and in the process gained a reputation as an outspoken visionary. But is he really as good as all that?
Sep 01, 2009
Pharmaceutical Executive
The obesity pipeline, despite a hugely underserved market potentially worth $11 billion, is awfully thin.
Sep 01, 2009
Pharmaceutical Executive
Big Pharma navigates a regulatory minefield to reach social media consumers. It's anything but 'business as usual.'
Aug 01, 2009
Pharmaceutical Executive
Innovative pharmaceutical companies are reaching out to physicians and consumers in an effort to get patients to take their medicine.
Aug 01, 2009
Pharmaceutical Executive
With the biotech industry reeling from the recession, big drugmakers hold all the cards when it comes to making deals, but picking a winner is still a gamble. Here are 10 to place stakes on.
Aug 01, 2009
Pharmaceutical Executive
The Belgian drugmaker is pursuing a sale, inking deals, issuing debt, and launching a power drug for Parkinson's—all at once.
Jul 07, 2009
Agency Confidential
Agency Insider Mark Chattaway infiltrates the world of online social media. His consensus: Advertising on social networks is iffy at best
native1_300x100
lorem ipsum